BioPharmSignal logoBioPharmSignal

Biotech News

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics (CYTK)CytokineticsCompany update

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2026 it granted stock options to purchase an aggregate of 60,465 shares of common stock and 40,084 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 29 employees, whose employment commenced in September and October 2026 as a material inducement to their employment.

Related news

CYTKCytokinetics2026-11-03 21:00 EST

Cytokinetics to Participate in November Investor Conferences

CYTKCytokinetics2026-11-02 12:30 EST

Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026

View all latest news

Cytokinetics

Muscle Biology Specialization Cytokinetics develops and commercializes medicines that modulate muscle function. Its portfolio is centered on cardiac muscle biology and diseases in which altered contractility contributes directly to symptoms and clinical outcomes. MYQORZO in Obstructive HCM MYQORZO, or aficamten, is a cardiac myosin...

Recent company news

CYTKCytokinetics2026-11-03 21:00 EST

Cytokinetics to Participate in November Investor Conferences

CYTKCytokinetics2026-11-02 12:30 EST

Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026

CYTKCytokinetics2026-10-21 20:00 EST

Cytokinetics to Announce Third Quarter Results on November 4, 2026

CYTKCytokinetics2026-10-19 20:00 EST

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CYTKCytokinetics2026-10-19 11:30 EST

Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Stock data

Close
55.55 USD
Market cap
9.63B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States